Rocket Pharma Q3 net loss $57.8M; cash $306.5M; Renovacor acquisition, LAD-I/FA filings on track

ROCKET PHARMACEUTICALS, INC.

2022-Q3 EPS reported -$2.37

Net loss $57.8M ($0.87/sh) vs $50.1M in Q3 2021; R&D expenses $43.4M, G&A $15.1M.
Cash, equivalents and investments $306.5M; after $108.2M equity offering, operational runway into 2H 2024.
Announced all-stock acquisition of Renovacor (implied ~$2.60/sh) to extend AAV cardiac gene therapy; expected close Q1 2023.
Danon Disease Phase 1 data positive; FDA feedback on Phase 2 pivotal design anticipated Q4 2022.
LAD-I regulatory filing expected 1H 2023, FA filing 2H 2023; PKD Phase 1 enrollment complete, Phase 2 pivotal in 2023.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

ROCKET PHARMACEUTICALS, INC. reported financial results for the quarter ended September 30, 2022.

Period: the quarter ended September 30, 2022
Result: reported results

Exact text from the filing

On November 3, 2022, Rocket Pharmaceuticals, Inc. announced its financial results for the quarter ended September 30, 2022.

View on SEC.gov

Browse all earnings releases →

ROCKET PHARMACEUTICALS, INC. filing history →

Source: SEC EDGAR

accession 0001140361-22-039875

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.